Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2/3 2Phase 4 1

Status

Completed 11Active not recruiting 6Recruiting 5Not yet recruiting 3Withdrawn 2Terminated 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Tumor-Agnostic 1Head & Neck 1Dermatologic 1

Conditions

Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thyroid Neoplasms 1Melanoma 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9toripalimab 8venetoclax 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7Carboplatin 7pembrolizumab 6irinotecan sucrosofate 6Temozolomide 6HMPL-013 6tislelizumab 5sintilimab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5Fluorouracil 5Etoposide 5Cisplatin 5Biopsy 5osimertinib 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × trametinib × Clear all
NCT07468071 2026-04-02

KontRASt-R

Novartis

Phase 1/2 Not yet recruiting
40 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05275374 2025-04-10

ENHANCE

Xynomic Pharmaceuticals, Inc.

Phase 1/2 Not yet recruiting
221 enrolled
DermatologicGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms

NCT06456138 2024-06-13

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Shanghai Chest Hospital

Phase 1/2 Not yet recruiting
60 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡